Medulloblastoma Genotype Dictates Blood Brain Barrier Phenotype.
暂无分享,去创建一个
M. Roussel | Yoon-Jae Cho | R. Gilbertson | D. Finkelstein | L. Goumnerova | C. Stewart | T. Phoenix | S. Perreault | N. Boulos | D. Patmore | Scott Boop | M. Jacus | Y. T. Patel | Elizabeth Wadhwa | Y. Patel | Deanna M. Patmore | Yogesh T Patel
[1] B. Pizer,et al. Posterior fossa syndrome following brain tumour resection: review of pathophysiology and a new hypothesis on its pathogenesis , 2015, Child's Nervous System.
[2] C. Mullighan,et al. Genomics in acute lymphoblastic leukaemia: insights and treatment implications , 2015, Nature Reviews Clinical Oncology.
[3] D. Ellison,et al. An in vivo screen identifies ependymoma oncogenes and tumor-suppressor genes , 2015, Nature Genetics.
[4] T. Gajewski,et al. Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity , 2015, Nature.
[5] Vivien Marx,et al. Cancer: A most exceptional response , 2015, Nature.
[6] Kenneth R. Parrish,et al. Improving drug delivery to primary and metastatic brain tumors: Strategies to overcome the blood–brain barrier , 2015, Clinical pharmacology and therapeutics.
[7] F. Cappuzzo,et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. , 2014, The New England journal of medicine.
[8] Giles W. Robinson,et al. Medulloblastoma—translating discoveries from the bench to the bedside , 2014, Nature Reviews Clinical Oncology.
[9] R. Jain,et al. Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia. , 2014, Cancer cell.
[10] J. Nathans,et al. Canonical WNT signaling components in vascular development and barrier formation. , 2014, The Journal of clinical investigation.
[11] D. Rowitch,et al. Oligodendrocyte-Encoded HIF Function Couples Postnatal Myelination and White Matter Angiogenesis , 2014, Cell.
[12] K. Yeom,et al. MRI Surrogates for Molecular Subgroups of Medulloblastoma , 2014, American Journal of Neuroradiology.
[13] Michael Kahn,et al. Can we safely target the WNT pathway? , 2014, Nature Reviews Drug Discovery.
[14] C. Kuo,et al. Developmental and pathological angiogenesis in the central nervous system , 2014, Cellular and Molecular Life Sciences.
[15] A. Biankin,et al. Mining the genomes of exceptional responders , 2014, Nature Reviews Cancer.
[16] Roland Eils,et al. Genome sequencing of SHH medulloblastoma predicts genotype-related response to smoothened inhibition. , 2014, Cancer cell.
[17] Christina S. Leslie,et al. CSF-1R inhibition alters macrophage polarization and blocks glioma progression , 2013, Nature Medicine.
[18] M. Junttila,et al. Influence of tumour micro-environment heterogeneity on therapeutic response , 2013, Nature.
[19] Scott L. Pomeroy,et al. Medulloblastomics: the end of the beginning , 2012, Nature Reviews Cancer.
[20] C. Sander,et al. Genome Sequencing Identifies a Basis for Everolimus Sensitivity , 2012, Science.
[21] K. Plate,et al. Endothelial Wnt/β-catenin signaling inhibits glioma angiogenesis and normalizes tumor blood vessels by inducing PDGF-B expression , 2012, The Journal of experimental medicine.
[22] Steven J. M. Jones,et al. Subgroup-specific structural variation across 1,000 medulloblastoma genomes , 2012, Nature.
[23] Matthew J. Betts,et al. Dissecting the genomic complexity underlying medulloblastoma , 2012, Nature.
[24] Jill P. Mesirov,et al. MEDULLOBLASTOMA EXOME SEQUENCING UNCOVERS SUBTYPE-SPECIFIC SOMATIC MUTATIONS , 2012, Nature.
[25] Elaine R. Mardis,et al. Novel mutations target distinct subgroups of medulloblastoma , 2012, Nature.
[26] M. Roussel,et al. A mouse model of the most aggressive subgroup of human medulloblastoma. , 2012, Cancer cell.
[27] F. Charron,et al. The Hedgehog Pathway Promotes Blood-Brain Barrier Integrity and CNS Immune Quiescence , 2011, Science.
[28] L. Pusztai,et al. Gene expression profiling in breast cancer: classification, prognostication, and prediction , 2011, The Lancet.
[29] W. Yung,et al. An integrated in vitro and in vivo high-throughput screen identifies treatment leads for ependymoma. , 2011, Cancer cell.
[30] Hendrik Witt,et al. Medulloblastoma comprises four distinct molecular variants. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] Bengt R. Johansson,et al. Pericytes regulate the blood–brain barrier , 2010, Nature.
[32] B. Barres,et al. Pericytes are required for blood–brain barrier integrity during embryogenesis , 2010, Nature.
[33] B. Barres,et al. The Mouse Blood-Brain Barrier Transcriptome: A New Resource for Understanding the Development and Function of Brain Endothelial Cells , 2010, PloS one.
[34] Yiai Tong,et al. Subtypes of medulloblastoma have distinct developmental origins , 2010, Nature.
[35] G. Kruh,et al. Influence of blood-brain barrier efflux pumps on the distribution of vincristine in brain and brain tumors. , 2010, Neuro-oncology.
[36] M. Corada,et al. The Wnt/beta-catenin pathway modulates vascular remodeling and specification by upregulating Dll4/Notch signaling. , 2010, Developmental cell.
[37] J. Nathans,et al. Norrin, Frizzled-4, and Lrp5 Signaling in Endothelial Cells Controls a Genetic Program for Retinal Vascularization , 2009, Cell.
[38] R. Moon,et al. Transcription-based reporters of Wnt/beta-catenin signaling. , 2009, Cold Spring Harbor protocols.
[39] Calvin J Kuo,et al. Wnt/β-catenin signaling is required for CNS, but not non-CNS, angiogenesis , 2009, Proceedings of the National Academy of Sciences.
[40] Andrew P. McMahon,et al. Canonical Wnt Signaling Regulates Organ-Specific Assembly and Differentiation of CNS Vasculature , 2008, Science.
[41] Robert Machold,et al. Medulloblastoma can be initiated by deletion of Patched in lineage-restricted progenitors or stem cells. , 2008, Cancer cell.
[42] H. Aburatani,et al. Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer , 2007, Nature.
[43] K. Hynynen,et al. Chemotherapy delivery issues in central nervous system malignancy: a reality check. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[44] T. Merchant,et al. Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial. , 2006, The Lancet. Oncology.
[45] T. Curran,et al. Genomics identifies medulloblastoma subgroups that are enriched for specific genetic alterations. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[46] M. Hatten,et al. The tumor suppressors Ink4c and p53 collaborate independently with Patched to suppress medulloblastoma formation. , 2005, Genes & development.
[47] Claire L Weston,et al. beta-Catenin status predicts a favorable outcome in childhood medulloblastoma: the United Kingdom Children's Cancer Study Group Brain Tumour Committee. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[48] J. Kessler,et al. Loss of patched and disruption of granule cell development in a pre-neoplastic stage of medulloblastoma , 2005, Development.
[49] J. Heimans,et al. Dose-related vincristine-induced peripheral neuropathy with unexpected off-therapy worsening , 2005, Neurology.
[50] R. Nusse,et al. The Wnt signaling pathway in development and disease. , 2004, Annual review of cell and developmental biology.
[51] S. Grossman,et al. Penetration of intra-arterially administered vincristine in experimental brain tumor. , 2004, Neuro-oncology.
[52] J A Firth,et al. Endothelial barriers: from hypothetical pores to membrane proteins * , 2002, Journal of anatomy.
[53] V. Perry,et al. Loss of the tight junction proteins occludin and zonula occludens-1 from cerebral vascular endothelium during neutrophil-induced blood–brain barrier breakdown in vivo , 1998, Neuroscience.
[54] M. Scott,et al. Altered neural cell fates and medulloblastoma in mouse patched mutants. , 1997, Science.
[55] A. Schinkel,et al. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. , 1996, The Journal of clinical investigation.
[56] A. Tonnel,et al. Endothelial cells , 1991 .